9I果冻制作厂官网

目录产物 » 抗体产物 » 一抗 » MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), mAb, Rabbit
Manual
SDS
COAs
L02087A)
SARS-CoV-2 B.1.617.2 (Delta) Pseudovirus Neutralization Assay kit _Luc reporter (GenScript, L02087V)
SARS-CoV-2 B.1.1.529 (Omicron) Pseudovirus Neutralization Assay kit _Luc reporter (GenScript, L02087-027)

MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), mAb, Rabbit (GenScript, A02051) dilutions start from 40 ?g/ml.
" data-src="/product/documents/down?doc_name=A02051-pVNT.jpg&file=scm_files/productFile_notes/2022/03/15/a3b5f616-17a7-429b-8dd7-58b18b6b06e7.jpg">

MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), mAb, Rabbit

The product is specific for SARS-CoV-2 Spike Protein S1 subunit and its RBD domain. The product can recognize and neutralize Wild-Type SARS-CoV-2 and five Variants of Concern (VOC) including Alpha, Beta, Gamma, Delta, and Omicron.
￥2800
A02051-100

产物概述
Specificity The product is specific for SARS-CoV-2 Spike Protein S1 subunit and its RBD domain.
The product can recognize and neutralize Wild-Type SARS-CoV-2 and five Variants of Concern (VOC) including Alpha, Beta, Gamma, Delta, and Omicron.
Host Species Rabbit
Immunogen Recombinant SARS-CoV-2 Spike protein fragment
Conjugate Unconjugated
返回

应用指导
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
Application Recommended Usage
ELISA 0.01-0.1 ?g/ml
Flow Cytometry 10 ?g/ml
Surrogate Virus Neutralization Test (sVNT) 0.1-1 ?g/ml
返回

产物属性
Form Liquid
Storage Buffer 0.2 μm filtered solution in PBS, pH 7.4
Concentration 1 mg/ml
Storage Instructions Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. Avoid repeated freezing and thawing cycles.
Purification Protein A affinity column
Isotype Rabbit IgG
Clonality Monoclonal
Clone ID BS-R2B2
Note GenScript can customize this product per customer's request including product size, buffer components, etc.
返回

图例
MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), MAb, Rabbit

ELISA binding of MonoRabTM SARS-CoV-2 Neutralizing Antibody (BS-R2B2), mAb, Rabbit (GenScript, A02051) with recombinant SARS-CoV-2 Spike Protein S1 RBD(GenScript, Z03483) and SARS-CoV RBD. ?

MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), MAb, Rabbit

Standard curve of SARS-CoV-2 Spike Protein Sandwich ELISA. The SARS-CoV-2 Spike Protein Sandwich ELISA assay is developed by using MonoRabTM SARS-CoV-2 Spike S1 Antibody (BS-R2B12), mAb, Rabbit (GenScript, A02058) and MonoRabTM SARS-CoV-2 Neutralizing Antibody (BS-R2B2), mAb, Rabbit (Genscript, A02051) as the capture and detection antibodies, respectively.
In this ELISA assay, MonoRabTM SARS-CoV-2 Neutralizing Antibody (BS-R2B2), mAb, Rabbit (Genscript, A02051) was labeled with HRP.
The sensitivity of detecting SARS-CoV-2 spike protein is up to 60 pg/ml. ?

MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), MAb, Rabbit

MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), mAb, Rabbit (GenScript, A02051) blocks SARS-CoV-2 wild-type and VOC RBDs binding with Human ACE2 recombinant protein by sVNT.

SARS-CoV-2 S-RBD WT (GenScript, Z03483)
SARS-CoV-2 S-RBD Alpha/B.1.1.7 (GenScript, Z03533)
SARS-CoV-2 S-RBD Beta/B.1.351 (GenScript, Z03537)
SARS-CoV-2 S-RBD Gamma/P.1 (GenScript, Z03600)
SARS-CoV-2 S-RBD Delta/B.1.617.2 (GenScript, Z03613)

MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), mAb, Rabbit dilution start from 10 ?g/ml. ?

MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), MAb, Rabbit

MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), mAb, Rabbit (GenScript, A02051) blocks SARS-CoV-2 Omicron RBD binding with Human ACE2 recombinant protein by sVNT.

SARS-CoV-2 S-RBD Omicron/B.1.1.529 (GenScript, )
MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), mAb, Rabbit dilution start from 10 ?g/ml. ?

MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), MAb, Rabbit

Pseudovirus Neutralization Test of SARS-CoV-2 pseudovirus–hACE2 interaction with MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), mAb, Rabbit (GenScript, A02051).

Control: HEK293/ACE2 cells were infected with SARS-CoV-2 pseudovirus
SARS-CoV-2 Pseudovirus Neutralization Assay kit_Luc reporter (GenScript, L02087A)
SARS-CoV-2 B.1.617.2 (Delta) Pseudovirus Neutralization Assay kit _Luc reporter (GenScript, L02087V)
SARS-CoV-2 B.1.1.529 (Omicron) Pseudovirus Neutralization Assay kit _Luc reporter (GenScript, L02087-027)

MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), mAb, Rabbit (GenScript, A02051) dilutions start from 40 ?g/ml.
?

MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), MAb, Rabbit

Dose-response curve of MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), mAb, Rabbit (GenScript, A02051) on SARS-CoV-2 Multiplex sVNT.

The final concentration of RBD recombinant proteins were 60 ng/mL. MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), mAb, Rabbit (GenScript, A02051) dilutions started from 10 ?g/mL.
MonoRab? SARS-CoV-2 Neutralizing Antibody (BS-R2B2), mAb, Rabbit (GenScript, A02051) can block the binding of SARS-CoV-2 omicron BQ.1.1 variant to Human ACE2, but it does not block the binding of XBB variant to Human ACE2. ?

<
>

技术背景
Target Background SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), also known as 2019-nCoV, is a positive-sense single-stranded RNA virus. It caused coronavirus disease 2019 (COVID-19). SARS-CoV-2 contains glycosylated spike (S) protein, which is composed of S1 subunit and S2 subunit. The S1 contains a receptor-binding domain (RBD) that can bind to ACE2 receptor on target cells.
Synonyms 2019-nCoV Neutralizing Antibody, mAb, Rabbit
返回

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.


相关文献
Shi-Hsia Hwa, et al. Association Between Human Immunodeficiency Virus Viremia and Compromised Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant. J Infect Dis. (2023-01)
Khadija Khan, et al. Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26CoV2S Vaccination in People Living With Human Immunodeficiency Virus (HIV). Clin Infect Dis. (2022-08)
Michelle H Teplensky, et al. Spherical nucleic acids as an infectious disease vaccine platform. Proc Natl Acad Sci U S A. (2022-03)
Dániel Petrovszki, et al. Penetration of the SARS-CoV-2 Spike Protein across the Blood-Brain Barrier, as Revealed by a Combination of a Human Cell Culture Model System and Optical Biosensing. Biomedicines. (2022-01)
Dániel Petrovszki, et al. Penetration of the SARS-CoV-2 Spike Protein across the Blood-Brain Barrier, as Revealed by a Combination of a Human Cell Culture Model System and Optical Biosensing. Biomedicines. (2022-01)
Sandile Cele, et al. SARS-CoV-2 evolved during advanced HIV disease immunosuppression has Beta-like escape of vaccine and Delta infection elicited immunity. medrxiv. (2021-12)
Sandile Cele, et al. Escape of SARS-CoV-2 501YV2 from neutralization by convalescent plasma. Nature. (2021-03)